top of page
Vivarus Biopharma is a biopharma company headquartered in Switzerland , with a dedicated team of rare-disease experts with strong patient-focus.

VIVARUS

BIOPHARMA

Making a Difference: Changing Lives

We are an international pharmaceutical company focused on commercializing specialty pharmaceuticals for severe diseases.

Our focus is on specialty therapeutics that require a strong medical focus and excellent relationships with medical and scientific establishments.

Our founders successfully launched multiple therapies in Europe, US and Asia-Pacific for leading corporations such as Hoffmann-La Roche, Amgen, Alexion, Biogen and EUSA Pharma.

Through our unique approach, we secured market leadership for iconic brands such as Mabthera, Neulasta, Aranesp, Soliris, Qarziba and Sylvant.

We have completed successful pricing and reimbursement negotiations since 20 years in all European markets, Canada, Australia, South America and secured early access in France, Italy, Spain, Russia and Belgium.

The team has a unique track record in oncology, haematology, endocrinology and metabolics launching innovative pharmaceuticals successfully through access & reimbursement and commercial-excellence in Europe.

What Makes Us Unique

We are parents, sons, daughters, brothers, sisters, and have personal experience of family with severe illnesses.

We are motivated by helping patients.

We want to be trusted ambassadors for the medical and scientific community.

Science and patient outcomes matter.

Creating a great working environment.

Treasure experience and embrace innovation.

Working every day towards being the best team, motivated by our purpose.

Live our values.

Delivering outstanding results.

oncology, hematology, endocrinology treatment
oncology, haematology, endocrinology for cancer treatment

The more suffering we see in patients the more we are motivated to go the extra mile.

partner of choice for commercialization of specialty pharma products to address devastating-diseases

Our Founders

Vivarus Biopharma log0
eusa pharma
Alexion logo
AMgen logo
Roche logo
Biogen logo
BI - boernger logo
Dr. Carsten Thiel PhD

Dr. Carsten Thiel PhD

Chief Executive Officer

Previously:

EUSA:    CEO and Board 

Alexion:  EVP and CCO 

Amgen:   VP, Head of Europe
Roche:    Global Business Lead / GM

Dr. Dev Kumar MD, JD and NED

Dr. Dev Kumar MD, JD and NED

Chief Legal Officer

Previously:

EUSA:    GC, CCO, & CoSec

NWEH: NED

Biogen: Director UKI, Canada, MENA

BI:          Head of Legal UKI

Testimonials & Awards

2010

“Best place to work award” in Germany

2018

Prix Galien Orphan Product Runner- Up (Qarziba)

2019

"European Deal of the Year" award at the LSX Life Stars awards

2019

Qarziba and Sylvant listed for fast-track approval in China by the NMPA via its Review and Approval Procedures for Urgently-Needed Pharmaceutical Drugs Developed Overseas

2020

Sunday Times Sage Tech Track 100 (fastest-growing sales)

2021

Entry in UK Parliament's 300 Years of Leadership & Innovation

2021

Sunday Times Sage Tech Track 100 (fastest-growing sales)

Our motivation is to help patients, who are in great need.

Our Values

Patient focus

Making a meaningful difference to people living with severe medical conditions, who have limited or no options for treatment. We place patients, their families, and carers at the centre of our mission.

Collaboration

Working together in connecting our expertise, patient insights, medical and scientific network, and innovative thinking to unhinge the full potential of our team.

Commitment

Engagement, perseverance, and dedication. We understand our duty to our patients.

Trust

Engage and rely on our relationships, driving every decision we make to ensure transparency, reliability, and unwavering commitment to team.

Partnering

With people and companies who share our values. Using the best scientists and third parties to deliver strong data and consistent quality, to deliver meaningful treatments to patients globally.

Product Launches

We like to be the partner of choice for commercialization of specialty pharma products to address devastating-diseases with high unmet-medical-need.

Contact Us

Would you like to partner with us?

Product Launches